menu ☰
menu ˟

Upadacitinib superior to placebo, adalimumab in active RA on methotrexate

26 Oct 2018
CHICAGO — Among patients with rheumatoid arthritis who experienced an inadequate response to methotrexate, a daily 15-mg dose of the JAK1 inhibitor upadacitinib was superior to both placebo and adalimumab at improving disease signs and symptoms.Add...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.